Using a MIF inhibitor and inflammatory factor GM-CSF, we successfully reprogram protumoral MΦ derived from peripheral blood of healthy donors (HD) and from autologous BM of AML patients into antitumoral/inflammatory M1-like MΦ. Here, MIF is linked to acute myeloid leukemia.